Pancreas Cancer Research Workshop 2016

The AGITG and the APC hosted the 4th annual Pancreas Cancer Workshop on Tuesday 13 September, immediately preceeding the AGITG ASM. The meeting was a resounding success with very good attendance across disciplines and robust, research-centred discussion. We had two outstanding invited speakers, the first was Professor Ben-Josef, a distinguished … Read More

September 19, 2016

INTEGRATE II set to open

In 2015, the AGITG brought together leaders in gastro-oesophageal cancer from around the globe to design a major phase III study based on the promising results of the INTEGRATE  study.  Support for the final INTEGRATE II trial design was received from Bayer in November 2015.  INTEGRATE II is a Randomised … Read More

September 9, 2016

New Concepts at ASM

The New Concepts Symposium sponsored by Specialised Therapeutics Australia (STA) is designed as a novel way to reach out to a wider spectrum of the group. This session provides an opportunity for delegates to present embryonic new concepts for feedback and discussion with the audience as well as comments from international … Read More

September 9, 2016

AGITG Trial News

The AGITG currently has six studies open to recruitment and ten studies in follow up. Please find following, a table indicating the trials that are still recruiting, and where the recruited patient numbers measure up against the trial target. Recruited Target ACTICCA-1- gallbladder carcinoma 0 50 ALT-GIST- GI Stromal Tumour 22 240 ASCOLT … Read More

September 7, 2016

NSW awards outstanding cancer researcher

Professor John Simes, AGITG Director and Director of the National Health and Medical Research Centre (NHMRC) has been awarded the NSW Premier’s Award for Outstanding Cancer Research. This is an annual award and the leading NSW awards program that celebrates excellence and innovation in cancer research. Professor John Simes is … Read More

August 8, 2016

AGITG @ ESMO 2016

This year the AGITG will be well represented at the European Society For Medical Oncology, (ESMO) the leading European professional organisation for medical oncology. In 2016 the ESMO Congress conference will be held in Denmark, Copenhagen from 7-11 October. Abstracts will include: the DOCTOR clinical trial; the MAX study; CO.17-CO.20; and CO.23. … Read More

August 4, 2016

Minimising missing PRO data

Patient-reported outcomes provide information about the impact of disease and treatment on the patient, and PROs can be interpreted in the context of other trial outcomes to provide a comprehensive assessment of treatment benefits and harms. PRO studies often suffer from missing data, which, if not handled appropriately, can cause … Read More

August 4, 2016

InterAACT now open at several sites

InterAACT is an international, multicentre trial aiming to establish which chemotherapy regimen is more effective for rare inoperable advanced or metastatic anal cancer. By comparing two well-known and widely used combination chemotherapies (cisplatin plus 5-fluorouracil versus carboplatin plus weekly paclitaxel), we aim to demonstrate which one is more effective and … Read More

August 2, 2016

ACTICCA-1 open to recruitment

Recently, ACTICCA-1 was opened for recruitment at the Bankstown-Lidcombe Hospital in NSW. This is a multicentre, prospective, randomized, controlled phase III trial designed to assess the clinical performance of gemcitabine with cisplatin and observation versus observation alone in patients after curative intent resection of cholangiocarcinoma (CCA) and muscle invasive gallbladder … Read More

August 2, 2016

TACTIC Study published

The AGITG TACTIC study, a Phase II trial of gemcitabine, cisplatin and panitumumab in biliary tract cancer was recently published in the Cancer Chemotherapy and Pharmacology Journal. The aim of the study was to determine the activity and safety gemcitabine, cisplatin and panitumumab in patients with K-ras wild-type locally advanced, … Read More

July 4, 2016